Latest research into retatruptide peptide highlight promising potential for treating weight and non-insulin dependent disease. The compound, a dual activator of glucagon-like peptide-1 and GIP receptor, looks to present improved weight reduction and glucose control versus existing medications. Additional patient studies are needed to completely det